-

01:17:57 PM

LIVE Real Time ORMP Stock Market News

ORMP - Oramed Pharmaceuticals, Inc

04/21/21 7:25 AM

Nasdaq : ORMP

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and Specialty Pharma

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand

RHEA-AI

neutral

03/23/21 8:53 AM

Nasdaq : ORMP

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its ORA-D-013-2 study, the

RHEA-AI

neutral

03/23/21 8:51 AM

Nasdaq : ORMP

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its ORA-D-013-2 study, the

RHEA-AI

neutral

03/19/21 8:40 AM

Nasdaq : ORMP

Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

Good candidate for protection against COVID variants due to triple antigen targeting Implications for potential ease of widescale distribution and administration anytime, anywhere for oral COVID-19 vaccine Efficacy following a single oral dose administration

RHEA-AI

neutral

03/16/21 8:25 AM

Nasdaq : ORMP

Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized 25% of the 675 patients planned for its

RHEA-AI

neutral

03/04/21 8:25 AM

Nasdaq : ORMP

Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C.

RHEA-AI

neutral

01/27/21 9:00 AM

Nasdaq : ORMP

Oramed Issues Letter to Shareholders

RHEA-AI

very positive

01/21/21 8:25 AM

Nasdaq : ORMP

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 study of its oral insulin

RHEA-AI

very positive

01/07/21 8:40 AM

Nasdaq : ORMP

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C.

RHEA-AI

neutral

12/23/20 8:25 AM

Nasdaq : ORMP

Oramed Reports Positive First in Human Data from Oral Leptin Study

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today results from a proof-of-concept study approved by Israel's Ministry of

RHEA-AI

neutral